Publicaciones en colaboración con investigadores/as de University of Milan (98)

2024

  1. Correlation between trophoblast cell-surface antigen-2 (Trop-2) expression and pathological complete response in patients with HER2-positive early breast cancer treated with neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab

    Breast Cancer Research and Treatment

  2. Disease prevalence in an urban raptor related to pest species: The case of Eurasian Scops Owl Otus scops infection by Gongylonema sp.

    Ibis, Vol. 166, Núm. 1, pp. 294-301

  3. Essential requirements for reporting radiation therapy in breast cancer clinical trials: An international multi-disciplinary consensus endorsed by the European Society for Radiotherapy and Oncology (ESTRO)

    Radiotherapy and Oncology

  4. Gender differences in the development of heart failure after acute coronary syndrome: Insight from the CORALYS registry

    International Journal of Cardiology, Vol. 397

  5. International multidisciplinary consensus on the integration of radiotherapy with new systemic treatments for breast cancer: European Society for Radiotherapy and Oncology (ESTRO)-endorsed recommendations

    The Lancet Oncology, Vol. 25, Núm. 2, pp. e73-e83

  6. Prognostic value of HER2DX in early-stage HER2-positive breast cancer: a comprehensive analysis of 757 patients in the Sweden Cancerome Analysis Network—Breast dataset (SCAN-B)

    ESMO Open, Vol. 9, Núm. 3

  7. Risk prediction of major cardiac adverse events and all-cause death following covid-19 hospitalization at one year follow-up: The HOPE-2 score

    European Journal of Internal Medicine

  8. Surrogate endpoints for overall survival in randomized clinical trials testing immune checkpoint inhibitors: a systematic review and meta-analysis

    Frontiers in Immunology, Vol. 15

  9. The evolving value assessment of cancer therapies: Results from a modified Delphi study

    Health Policy OPEN, Vol. 6

2023

  1. COVID-19 epidemic spread and green areas Italy and Spain between 2020 and 2021: An observational multi-country retrospective study

    Environmental Research, Vol. 216

  2. Cardiac Safety and Efficacy of SB3 Trastuzumab Biosimilar for ERBB2-Positive Early Breast Cancer: Secondary Analysis of a Randomized Clinical Trial

    JAMA Network Open, Vol. 6, Núm. 4, pp. E235822

  3. Correction to: Improving clinical paediatric research and learning from COVID-19: recommendations by the Conect4Children expert advice group (Pediatric Research, (2022), 91, 5, (1069-1077), 10.1038/s41390-021-01587-3)

    Pediatric Research

  4. DESTINY-Breast03 trial: some questions remain – Authors' reply

    The Lancet

  5. ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer

    Annals of Oncology, Vol. 34, Núm. 8, pp. 645-659

  6. Evaluation of triple negative breast cancer with heterogeneous immune infiltration

    Frontiers in Immunology, Vol. 14

  7. Forecasting the Risk of Heart Failure Hospitalization After Acute Coronary Syndromes: the CORALYS HF Score

    American Journal of Cardiology, Vol. 206, pp. 320-329

  8. Impact of Complete Revascularization on Development of Heart Failure in Patients With Acute Coronary Syndrome and Multivessel Disease: A Subanalysis of the CORALYS Registry

    Journal of the American Heart Association, Vol. 12, Núm. 15, pp. e028475

  9. IncidenCe and predictOrs of heaRt fAiLure after acute coronarY Syndrome: The CORALYS registry

    International Journal of Cardiology, Vol. 370, pp. 35-42

  10. Management of patients with HER2-positive metastatic breast cancer after trastuzumab deruxtecan failure

    ESMO Open, Vol. 8, Núm. 4

  11. Margetuximab Versus Trastuzumab in Patients With Previously Treated HER2-Positive Advanced Breast Cancer (SOPHIA): Final Overall Survival Results From a Randomized Phase 3 Trial

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 41, Núm. 2, pp. 198-205